Glenmede Trust’s Insys Therapeutics, Inc. INSY Stock Holding History

Glenmede Trust’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-545	Closed	-$1	–	3247
2018 Q4	$1	Buy	+545	New	+$3.79K	﹤0.01%	2967
2015 Q4	–	Sell	-622,293	Closed	-$17.7M	–	2835
2015 Q3	$17.7M	Buy	622,293 +118,820	+24%	+$4.37M	0.13%	262
2015 Q2	$18.1M	Buy	+503,473	New	+$15.7M	0.13%	260

Other funds holding INSY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Glenmede Trust's INSY Position: Q1 2019 in Review

Glenmede Trust sold out of Insys Therapeutics, Inc. (INSY) in Q1 2019, closing a stake of 545 shares — an estimated $1 sold.

Glenmede Trust first reported a position in INSY in Q2 2015 and held it in 3 quarters. The position peaked at $18.1M in Q2 2015. 98 funds tracked by Wall St. Rank hold INSY as of Q1 2019.

Glenmede Trust reported no remaining Insys Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Glenmede Trust sold 545 Insys Therapeutics, Inc. shares in Q1 2019, an estimated $1.
Glenmede Trust first reported a position in Insys Therapeutics, Inc. in Q2 2015 and held it in 3 quarters.
Glenmede Trust's Insys Therapeutics, Inc. position peaked at $18.1M in Q2 2015.
98 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2019.

Based on Glenmede Trust's 13F filing for Q1 2019, filed 14 May 2019.